Hofseth Biocare ASA: CONTEMPLATING UNSECURED BOND ISSUANCE

10 Mar 2025 08:00 CET

Hofseth BioCare ASA has retained Novum Asset Management AG to investigate the
potential issuance of CHF-denominated unsecured bonds with an expected volume of
up to CHF 8 million, towards investors in Switzerland and Liechtenstein.
Further, the Company may contact investors in Norway directly. The Company
targets a tenor of three years for the Bonds.

Further information about any issuance of Bonds, and the terms and conditions of
such bonds, will be given in due course.

For further information, please contact:
Jon Olav Ødegård, CEO at HBC
Phone: +47 936 32 966
E-mail: joo@hofsethbiocare.no

About Hofseth BioCare ASA:

Hofseth BioCare is a Norwegian consumer and pet health company founded on the
core values of sustainability, optimal utilization of natural resources and full
traceability. It upcycles the side streams of the salmon industry by taking
fresh filleted salmon and converting it from a waste product into ingredients to
improve human and pet health. These ingredients are ProGo®, a mix of bioactive
peptides and collagen, OmeGo®, a whole salmon oil, with all the fatty acid
fractions contained in fish, and CalGo® / NT-II(TM) salmon bone powder
containing
calcium hydroxyapatite and undenatured collagen for bone and joint health. HBC
places scientific evidence at the forefront which has led to important academic
partnerships and the identification of unique health benefits. This includes the
demonstration of improved iron metabolism by boosting the body's ability to take
up and use iron resulting in increased energy and vitality with ProGo® as well
as the activation of the GLP-1 receptor with fat reduction in overweight adults.
OmeGo® has shown important immune health benefits including recovery from viral
infection and improved respiratory health and sleep in adults troubled by
particulate matter pollution. Finally, CalGo® has shown both bone and joint
health benefits to support healthy ageing and active lifestyles. This work has
also resulted in the granting of several patents protecting these discoveries.
It has also led to the discovery of potential therapeutics and HBC has spun out
a biotech-focused company, HBC Immunology (HBCI). HBCI has raised external
finance, and the lead program is in prostate cancer followed by ovarian cancer.
A separate molecule is targeted as an oral, steroid-sparing therapy for asthma.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site